WFH, Sanofi and Sobi for Armenia: Unprecedented Commitment to Build the Humanitarian Aid Program
Scott Williams, VP and Head, Global Public Affairs at Sanofi, shared an honoring post on LinkedIn:
”In 2014, the World Federation of Hemophilia (WFH) put out a call to action to join them and build their Humanitarian Aid (HA) Program into a more sustainable and predictable solution. Sanofi, along with Sobi, responded with an unprecedented commitment – to provide 1 billion IUs of factor therapy over 10 years. This commitment drove other companies to collaborate with the WFH HA Program and together, we empowered the WFH to provide treatment not only for life-saving surgeries but also for acute bleeds and prophylaxis in children.
I have just returned from a Humanitarian Aid visit with the World Federation of Hemophilia to Armenia. It is with humility that I share a look into 5 extraordinary days together.
It was so impactful to see the before and after progress that’s been made over the past 10+ years in Armenia. We saw a strong hemophilia treatment center and integrated multi-disciplinary care team, access to factor therapy, ability to have prophylaxis treatment at home, impactful local patient organization (NMO), and more. Meeting and hearing the stories of patients and families whose lives have been forever transformed truly puts the “human” in the humanitarian program. It is a powerful reminder of the good that can be achieved when we work together with a shared purpose.
At Sanofi, we are working as a committed industry partner with stakeholders across the bleeding disorders community to drive forward comprehensive, patient-centric solutions that go Beyond the Bleed to meaningfully advance the care paradigm. Envisioning a future beyond the bleed lies at the heart of our mission.
I will never be the same after the visit to Armenia with the WFH. The tears, hope, smiles, determination, and perseverance of children and family members living with hemophilia ensured that I will continue to be a deeply committed Rare Ambassador.”
More encouraging stories featured in Hemostasis Today.
-
Sep 23, 2026, 16:04Monia Ezzalfani: Advancing Patient-Centered Care in Hemophilia A and B
-
Sep 23, 2026, 15:49Bilge Başak: How Activated PRP Modulates Osteoarthritic Chondrocyte Function
-
Sep 23, 2026, 14:50Mbonjo Bitsie Dora: Strengthening Sickle Cell Care Through Education, Awareness and Innovation
-
Sep 23, 2026, 13:58The New B12 Diagnostic Algorithm: From Serum Cobalamin to Functional Deficiency
-
Sep 23, 2026, 13:56Noha Soror: Preparing for Hematology and Medical Oncology Board Certification
-
Sep 23, 2026, 13:46Ugochi Ogu: What Can Platelet Proteomics Reveal about Pain and Neurocognitive Vulnerability in Sickle Cell Disease?
-
Sep 23, 2026, 13:42Melissa Hollo: Connecting Obesity and Anemia for Earlier Maternal Risk Intervention
-
Sep 23, 2026, 13:16Beverley Hunt: Advances in Haemostatic Management of Postpartum Haemorrhage
-
Sep 23, 2026, 13:13Ioanna Mela: Recruiting a Research Associate on DNA nanotechnology